Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 25, 2025Frontiers in OncologyOpen Access

Prognostic factors and treatment outcomes in EGFR-mutated NSCLC with malignant pleural effusion: focus on intrathoracic chemotherapy and EGFR-TKI therapy

View Full Paper
Ask AI
Bookmark
Share

Authors

ZHZhou HuangJLJinmei LiHYHaiyin Ye

Discussion

Loading...

Member takes

Implication

Retrospective analysis reveals the impact of adding intrathoracic chemotherapy to EGFR-TKI treatment in stage IVA-IVB NSCLC with malignant pleural effusion, suggesting further exploration is needed.

Key Points

  • No significant differences in progression-free survival between EGFR-TKI monotherapy and combined therapy with intrathoracic chemotherapy.
  • Use of third-generation EGFR-TKIs and exon 19 deletions are linked to longer progression-free survival for patients.
  • A retrospective analysis included 169 patients diagnosed with stage IVA-IVB NSCLC with EGFR mutations and malignant pleural effusion.
  • Results underscore that while ICT added to EGFR-TKIs does not enhance outcomes, third-generation TKIs show promise for these patients.

Cite This Study

Huang et al. (2025) studied this question.

synapsesocial.com/papers/68d5bd6edc445aa9033b09f8https://doi.org/10.3389/fonc.2025.1667197
View Full Paper
Ask AI
Bookmark
Share